poisar

Stock

Jazz Pharmaceuticals plc Common Stock (Ireland) JAZZ

$244.32-0.62%

Overview

JAZZ market data

Price History

JAZZ price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
16.97
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$5.84
Diluted earnings per share over the trailing twelve months.
Beta
0.36
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
20.5%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$112.49 – $265.05
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $16B · P/B 2.39 · P/S 3.47.

Company News

10 captured
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $283Benzinga · Aug 11, 2026, 3:51 PM
8-K filing — Jazz Pharmaceuticals plc (JAZZ)SEC EDGAR · Aug 10, 2026, 9:13 PM
Jazz Pharmaceuticals To Acquire Developer Of Epilepsy Therapy Biotech Actio Biosciences For $820M Up Front And Up To $500M In ContingenciesBenzinga · Aug 10, 2026, 11:37 AM
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $276Benzinga · Aug 4, 2026, 6:52 PM
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $264Benzinga · Aug 4, 2026, 4:41 PM
TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300Benzinga · Aug 4, 2026, 4:30 PM
Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300Benzinga · Aug 4, 2026, 1:18 PM
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $280Benzinga · Aug 4, 2026, 12:35 PM
Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310Benzinga · Aug 4, 2026, 12:04 PM
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 ResultsBenzinga · Aug 4, 2026, 11:54 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock